

UNITED STATE

PARTMENT OF COMMERCE

Patent and Trade...ark Offic

Address:

COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO.

08/630,383 04/10/96 POULETTY

 P
 A-55320-2/BI

 ART UNIT
 PAPER NUMBER

EXAMINER

HM22/1004

FLEHR HOHBACH TEST ALBRITTON AND HERBERT SUITE 3400 FOUR EMBARCADERO CENTER SAN FRANCISCO CA 94111-4187 DATE MAILEDWADRON, R

1644

10/04/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

BEST AVAILABLE COPY



Application No.

Office Action Summary

08/630,383

Examiner Ron Schwadron, Ph.D.

Pouletty et al. Group Art Unit

1644



Responsive to communication(s) filed on	·
 This action is FINAL. Since this application is in condition for allowance except for in accordance with the practice under Ex parte Quayle, 1938. A shortened statutory period for response to this action is set to the communication. Failure 	o expire month(s), or thirty days, whichever
A shortened statutory period for response to this action is set to is longer, from the mailing date of this communication. Failure application to become abandoned. (35 U.S.C. § 133). Extensi 37 CFR 1.136(a).	to respond within the period to respond to respond within the period to respond to respo
Disposition of Claims	is/are pending in the application.
Disposition of Claims X Claim(s) 1-11 and 13	is/are withdrawn from consideration.
Of the above, claim(s)	is/are withdrawn from consideration. is/are allowed.
Claim(s)	
- Claim(s)	are subject to restriction or election requirement.
☐ Claim(s)	
Application Papers See the attached Notice of Draftsperson's Patent Drawi The drawing(s) filed on is/are obj The proposed drawing correction, filed on The specification is objected to by the Examiner. The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 Acknowledgement is made of a claim for foreign priorit	is approved disapproved. ty under 35 U.S.C. § 119(a)-(d). s of the priority documents have been Number) the International Bureau (PCT Rule 17.2(a)).
Attachment(s) Notice of References Cited, PTO-892 Information Disclosure Statement(s), PTO-1449, Paper Interview Summary, PTO-413 Notice of Draftsperson's Patent Drawing Review, PTO-152 Notice of Informal Patent Application, PTO-152	
SEE OFFICE ACTION	ON THE FOLLOWING PAGES

Art Unit 1644

- 1. Claims 1-11,13 are under consideration.
- 2. Restriction to one of the following inventions is required under 35 U.S.C. § 121:
- I. Claims 1-11 are drawn to a method of killing a target cell, classified in Class 424 subclass 193.1.
- II. Claim 13 is drawn to a method of reducing the concentration of a soluble target molecule in the blood stream., classified in Class 424 subclass 158.1.
- 3. The inventions are distinct, each from the other because of the following reasons:
- 4. Inventions I and II are different methods that use different ingredients to achieve different goals. Invention I is drawn to a method of killing a target cell, while invention II is drawn to a method of reducing the concentration of a soluble target molecule in the blood stream. Invention II uses a conjugate containing an antibody against a soluble molecule not used in the method of invention I. Therefore they are novel and unobvious in view of each other and are patentably distinct.
- 5. Because these inventions are distinct for the reasons given above and the search required for Group I is not required for Group II and Groups I and II have acquired a separate status in the art as shown by their different classification and divergent subject matter, restriction for examination purposes as indicated is proper.
- 6. If applicant elects Group I, the following species election is required.

This application contains claims directed to the following patentably distinct species of the claimed invention.

The method of claim 1 or 9 which uses a selective moiety wherein the selective moiety is

A)SEC1

B)SEA

C)ExFT

D)TSST1

E)Mls

F)minor histocompatibility antigen

G)a selective moiety that binds to anti- α gal antibodies (eg. α gal)

H)blood group antigen

I)a portion of a protein vaccine.

These molecules are structurally and functionally distinct.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

- 7. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.
- 8. Papers related to this application may be submitted to Group 1600 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). Papers should be faxed to Group 1600 at (703) 308-4242.



Serial No. 08/630383 Art Unit 1644

Any inquiry concerning this communication or earlier communications from the Examiner 9. should be directed to Dr. Ron Schwadron whose telephone number is (703) 308-4680. The examiner can normally be reached Monday through Thursday from 7:30 to 6:00. A message may be left on the examiners voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor, Ms Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1640 receptionist whose telephone number is (703) 308-0196.

Ron Schwadron, Ph.D.

Art Unit 1644

RONALD B. SCHWADRON PRIMARY EXAMINER GROUP 1898 (600)

Primary Examiner